Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer

Talazoparib, a potent PARP inhibitor, has shown promising clinical and pre-clinical activity by inducing synthetic lethality in cancers with germline Brca1/2 mutations. Conventional oral delivery of Talazoparib is associated with significant off-target effects, therefore we sought to develop new del...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Theranostics
Main Authors: Belz, Jodi E., Kumar, Rajiv, Baldwin, Paige, Ojo, Noelle Castilla, Leal, Ana S., Royce, Darlene B., Zhang, Di, van de Ven, Anne L., Liby, Karen T., Sridhar, Srinivas
Formato: Artigo
Idioma:Inglês
Publicado: Ivyspring International Publisher 2017
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5695017/
https://ncbi.nlm.nih.gov/pubmed/29158830
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.18563
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares